AP
FATE icon

AtonRa Partners’s Fate Therapeutics FATE Stock Holding History

AtonRa Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,035
Closed -$74.3K – 118
2023
Q1 		$74.3K Sell
13,035
-1,877
-13% -$11.3K 0.11% 121
2022
Q4 		$150K Sell
14,912
-4,034
-21% -$75.8K 0.19% 111
2022
Q3 		$425K Sell
18,946
-528
-3% -$15.3K 0.42% 99
2022
Q2 		$483K Sell
19,474
-1,223
-6% -$33.7K 0.44% 105
2022
Q1 		$802K Buy
20,697
+4,559
+28% +$177K 0.44% 89
2021
Q4 		$944K Buy
16,138
+1,644
+11% +$93.2K 0.33% 95
2021
Q3 		$859K Sell
14,494
-8,717
-38% -$684K 0.29% 105
2021
Q2 		$2.01M Buy
23,211
+1,344
+6% +$108K 0.74% 63
2021
Q1 		$1.8M Sell
21,867
-1,540
-7% -$148K 0.8% 52
2020
Q4 		$2.13M Buy
+23,407
New +$1.45M 1.04% 48

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

AtonRa Partners's FATE Position: Q2 2023 in Review

AtonRa Partners sold out of Fate Therapeutics (FATE) in Q2 2023, closing a stake of 13,035 shares — an estimated $74.3K sold.

AtonRa Partners first reported a position in FATE in Q4 2020 and held it in 10 quarters. The position peaked at $2.13M in Q4 2020. 188 funds tracked by Wall St. Rank hold FATE as of Q2 2023.

  • AtonRa Partners reported no remaining Fate Therapeutics position as of Q2 2023 after selling out during the quarter.
  • AtonRa Partners sold 13,035 Fate Therapeutics shares in Q2 2023, an estimated $74.3K.
  • AtonRa Partners first reported a position in Fate Therapeutics in Q4 2020 and held it in 10 quarters.
  • AtonRa Partners's Fate Therapeutics position peaked at $2.13M in Q4 2020.
  • 188 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2023.

Based on AtonRa Partners's 13F filing for Q2 2023, filed 18 Jul 2023.